Page last updated: 2024-12-09

malonyl coenzyme a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Malonyl Coenzyme A: A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

omega-carboxyacyl-CoA : An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID644066
CHEMBL ID1234355
CHEBI ID15531
SCHEMBL ID6450
MeSH IDM0012951

Synonyms (35)

Synonym
CHEMBL1234355
s-(hydrogen malonyl)coenzyme a
CHEBI:15531 ,
coenzyme a, s-(hydrogen propanedioate)
3'-phosphoadenosine 5'-{3-[(3r)-4-{[3-({2-[(3-carboxyacetyl)sulfanyl]ethyl}amino)-3-oxopropyl]amino}-3-hydroxy-2,2-dimethyl-4-oxobutyl] dihydrogen diphosphate}
thiomalonic acid s-ester with coenzyme a
coenzyme a, s-(hydrogen malonate)
malonyl-coenzyme a
s-malonyl-coa
9h-purin-6-amine,9-[5-o-[[[[[(3r)-4-[[3-[[2-[(carboxyacetyl)thio]ethyl]amino]-3-oxopropyl]amino]-3-hydroxy-2,2-dimethyl-4-oxobutyl]oxy]hydroxyphosphinyl]oxy]hydroxyphosphinyl]-3-o-phosphono-beta-d-rib
524-14-1
MALONYL-COA ,
omega-carboxyacyl-coa
malonyl coenzyme a
C00083
C03188
DB04524
3-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-3-oxopropanoic acid
malonyl coa
3-[(2-{3-[(2r)-3-[({[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-2-hydroxy-3-methylbutanamido]propanamido}ethyl)sulfanyl]-3-oxopropanoic acid
gtpl5219
SCHEMBL6450
J-002124
LMFA07050345
s-(hydrogen propanedioate) coa
omega-carboxyacyl-coenzyme a
s-(hydrogen propanedioate) coenzyme a
s-(hydrogen propanedioate
s-(hydrogen propanedioic acid
(3s,5r,9r)-1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18-thia-11,15-diaza-3,5-diphosphahenicosan-21-oic acid 3,5-dioxide (non-preferred name)
DTXSID40904351
Q51589793
bdbm50260111
HY-115899
CS-0379299

Research Excerpts

Overview

Malonyl coenzyme A (malonyl-CoA) is an important precursor for the synthesis of natural products, such as polyketides and flavonoids.

ExcerptReferenceRelevance
"Malonyl coenzyme A (malonyl-CoA) is an important precursor for the synthesis of natural products, such as polyketides and flavonoids. "( Fine-Tuning of the Fatty Acid Pathway by Synthetic Antisense RNA for Enhanced (2S)-Naringenin Production from l-Tyrosine in Escherichia coli.
Chen, J; Du, G; Wu, J; Yu, O; Zhou, J, 2014
)
1.85

Toxicity

ExcerptReferenceRelevance
" The data suggest that differences in intermediary metabolism render tumor cells susceptible to toxic fluxes in malonyl-CoA, both in vitro and in vivo."( Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Chrest, FJ; Frehywot, GL; Han, WF; Kuhajda, FP; Pinn, ML; Pizer, ES; Thupari, J; Townsend, CA, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetic profile very similar to that shown by the parent compound."( Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
Frenneaux, MP; Grant, DM; Greig, IR; Madhani, M; Noordali, H; Sani, M; Tseng, CC; Zanda, M, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound."( Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Obese Zucker rats were dosed orally for one week with fenofibrate (100 mg/kg)."( Effects of fenofibrate treatment on fatty acid oxidation in liver mitochondria of obese Zucker rats.
Bezard, J; Cao Danh, H; Clouet, P; Henninger, C; Pascal, M, 1987
)
0.27
" Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound."( Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019
)
0.51
" ACCi-1 dose-dependently suppressed facial sebum excretion by ~50% (placebo adjusted) in human individuals dosed orally for 2 weeks."( Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.
Amor, PA; Beysen, C; Biddle, KE; Bosanac, SS; Buckeridge, C; Carvajal-Gonzalez, S; Esler, WP; Fitch, M; Geoly, FJ; Gorgoglione, M; Griffith, DA; Hassoun, L; Hellerstein, MK; Pfefferkorn, JA; Purkal, JJ; Rolph, TP; Silvia, AM; Sivamani, R; Sonnenberg, GE; Tesz, GJ; Turner, SM; Vera, NB; Watkins, SM, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of mitochondrial carnitine O-palmitoyltransferase (EC 2.3.1.21).
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
malonyl-CoAsAny short-chain fatty acyl-CoA in which the the fatty acid specified is malonic acid or its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (14)

PathwayProteinsCompounds
Pyruvate metabolism ( Pyruvate metabolism )3027
Malonyl-CoA = Acetyl-CoA + CO2 ( Pyruvate metabolism )13
Mitochondrial fatty acid synthesis pathway08
Familial hyperlipidemia type 413
Leucine, isoleucine and valine metabolism2470
CBD synthetic pathway08
fatty acid biosynthesis -- elongase pathway012
AMPK signaling06
AMP-activated protein kinase signaling06
Metabolism overview078
Biochemical pathways: part I0466
Leptin and adiponectin02
Lipid metabolism pathway06
Effect of L-carnitine on metabolism09

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carnitine O-palmitoyltransferase 1, muscle isoformRattus norvegicus (Norway rat)IC50 (µMol)1.20000.38002.03255.1000AID1460781
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1460781Inhibition of Wistar rat heart mitochondrial CPT-1 assessed as reduction in conversion of palmitoyl CoA and L-carnitine into palmitoylcarnitine preincubated for 3 mins followed by L-carnitine and palmitoyl CoA addition measured for 3.5 mins by spectrophot2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,153)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990290 (25.15)18.7374
1990's237 (20.56)18.2507
2000's327 (28.36)29.6817
2010's229 (19.86)24.3611
2020's70 (6.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.16 (24.57)
Research Supply Index7.07 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index111.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.60%)5.53%
Reviews97 (8.30%)6.00%
Case Studies20 (1.71%)4.05%
Observational0 (0.00%)0.25%
Other1,045 (89.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]